FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to a compound of general formula (1) or a pharmaceutically acceptable salt thereof.
EFFECT: novel compounds are obtained, which have excellent inhibitory activity on IRAK-4 and can be used as active ingredients of medicinal agents for treating diseases associated with IRAK-4 inhibition.
35 cl, 31 tbl, 3 ex, 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PROTEOLYSIS MODULATORS AND RELATED USES | 2019 |
|
RU2805511C2 |
| MACROCYCLIC COMPOUND | 2020 |
|
RU2818822C1 |
| COMBINED TREATMENT BY A TOLL-LIKE RECEPTOR (TLR7) AGONIST AND A HEPATITIS B VIRUS CAPSID ASSEMBLY INHIBITOR | 2016 |
|
RU2718917C2 |
| ANTIBACTERIAL AGENT | 2000 |
|
RU2269525C2 |
| PYRIDOPYRIMIDINONE DERIVATIVES AND USE THEREOF AS AROMATIC HYDROCARBON RECEPTOR MODULATORS | 2021 |
|
RU2818954C1 |
| POLYCYCLIC DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL APPLICATION | 2012 |
|
RU2621039C1 |
| COMPOUNDS OF FORMULA (I) AND FORMULA (A), PHARMACEUTICAL COMPOSITION, MEDICINAL PRODUCT, USE AND METHOD OF OBTAINING COMPOUNDS OF FORMULA (I) | 2018 |
|
RU2822758C2 |
| 1-(4-ISOXAZOLE-5-YL)-1H-PYRAZOLE-1-YL)-2-METHYLPROPANE-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-17 AND IFN-GAMMA INHIBITORS FOR TREATMENT OF AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION | 2018 |
|
RU2785342C2 |
| THERAPEUTIC COMPOUNDS AND COMPOSITIONS | 2015 |
|
RU2733405C2 |
| HETEROCYCLIC COMPOUNDS, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2015 |
|
RU2667498C2 |
